WO2002072200A1 - Bestrahlungsanordnung_für therapeutische zwecke - Google Patents
Bestrahlungsanordnung_für therapeutische zwecke Download PDFInfo
- Publication number
- WO2002072200A1 WO2002072200A1 PCT/DE2002/000778 DE0200778W WO02072200A1 WO 2002072200 A1 WO2002072200 A1 WO 2002072200A1 DE 0200778 W DE0200778 W DE 0200778W WO 02072200 A1 WO02072200 A1 WO 02072200A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- irradiation
- arrangement according
- pulse
- radiation
- irradiation arrangement
- Prior art date
Links
- 230000001678 irradiating effect Effects 0.000 title abstract 6
- 230000001225 therapeutic effect Effects 0.000 title description 11
- 230000005855 radiation Effects 0.000 claims abstract description 104
- 230000003287 optical effect Effects 0.000 claims abstract description 29
- 230000003595 spectral effect Effects 0.000 claims abstract description 28
- 230000001404 mediated effect Effects 0.000 claims abstract description 11
- 201000004624 Dermatitis Diseases 0.000 claims abstract description 9
- 210000001835 viscera Anatomy 0.000 claims abstract description 6
- 238000011282 treatment Methods 0.000 claims description 45
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 23
- QKEOZZYXWAIQFO-UHFFFAOYSA-M mercury(1+);iodide Chemical compound [Hg]I QKEOZZYXWAIQFO-UHFFFAOYSA-M 0.000 claims description 23
- 239000001301 oxygen Substances 0.000 claims description 23
- 229910052760 oxygen Inorganic materials 0.000 claims description 23
- 238000001816 cooling Methods 0.000 claims description 16
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 9
- 229920002379 silicone rubber Polymers 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 5
- 239000012876 carrier material Substances 0.000 claims description 4
- 230000000699 topical effect Effects 0.000 claims description 3
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 2
- 229910052805 deuterium Inorganic materials 0.000 claims description 2
- 229920002313 fluoropolymer Polymers 0.000 claims description 2
- 239000004811 fluoropolymer Substances 0.000 claims description 2
- 230000001131 transforming effect Effects 0.000 claims description 2
- 229910005793 GeO 2 Inorganic materials 0.000 claims 1
- 229910052771 Terbium Inorganic materials 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 abstract description 7
- 230000004054 inflammatory process Effects 0.000 abstract description 7
- 210000004400 mucous membrane Anatomy 0.000 abstract description 6
- 208000035143 Bacterial infection Diseases 0.000 abstract description 3
- 208000035473 Communicable disease Diseases 0.000 abstract description 3
- 206010017533 Fungal infection Diseases 0.000 abstract description 3
- 208000031888 Mycoses Diseases 0.000 abstract description 3
- 230000003612 virological effect Effects 0.000 abstract description 3
- 102000029797 Prion Human genes 0.000 abstract description 2
- 108091000054 Prion Proteins 0.000 abstract description 2
- 208000015181 infectious disease Diseases 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 19
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 18
- 229910052733 gallium Inorganic materials 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 18
- 230000035515 penetration Effects 0.000 description 16
- 206010028980 Neoplasm Diseases 0.000 description 13
- 229910052753 mercury Inorganic materials 0.000 description 10
- 238000002428 photodynamic therapy Methods 0.000 description 10
- 238000001228 spectrum Methods 0.000 description 10
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 9
- 208000002874 Acne Vulgaris Diseases 0.000 description 7
- 206010000496 acne Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 208000017520 skin disease Diseases 0.000 description 7
- 238000002679 ablation Methods 0.000 description 6
- 230000017074 necrotic cell death Effects 0.000 description 6
- 238000001208 nuclear magnetic resonance pulse sequence Methods 0.000 description 6
- 150000004032 porphyrins Chemical class 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 238000009792 diffusion process Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000001126 phototherapy Methods 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 230000002123 temporal effect Effects 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 208000010668 atopic eczema Diseases 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 239000003990 capacitor Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- DWRNSCDYNYYYHT-UHFFFAOYSA-K gallium(iii) iodide Chemical compound I[Ga](I)I DWRNSCDYNYYYHT-UHFFFAOYSA-K 0.000 description 4
- 229910052738 indium Inorganic materials 0.000 description 4
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 230000000258 photobiological effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000010453 quartz Substances 0.000 description 4
- 239000003642 reactive oxygen metabolite Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 239000002826 coolant Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000003434 inspiratory effect Effects 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 239000013307 optical fiber Substances 0.000 description 2
- 238000006213 oxygenation reaction Methods 0.000 description 2
- 239000003504 photosensitizing agent Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000003313 weakening effect Effects 0.000 description 2
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- 208000020154 Acnes Diseases 0.000 description 1
- 229910000497 Amalgam Inorganic materials 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 230000010748 Photoabsorption Effects 0.000 description 1
- 208000024777 Prion disease Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010039580 Scar Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 208000000558 Varicose Ulcer Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 230000006003 cornification Effects 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000005281 excited state Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 230000009746 freeze damage Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 150000002259 gallium compounds Chemical class 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 230000017525 heat dissipation Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 230000001795 light effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- -1 mercury halide Chemical class 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 238000013021 overheating Methods 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 238000002640 oxygen therapy Methods 0.000 description 1
- 230000000803 paradoxical effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 238000006552 photochemical reaction Methods 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- 230000000191 radiation effect Effects 0.000 description 1
- 238000009418 renovation Methods 0.000 description 1
- 239000010980 sapphire Substances 0.000 description 1
- 229910052594 sapphire Inorganic materials 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 231100000617 superantigen Toxicity 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/0616—Skin treatment other than tanning
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
- H01J61/00—Gas-discharge or vapour-discharge lamps
- H01J61/02—Details
- H01J61/12—Selection of substances for gas fillings; Specified operating pressure or temperature
- H01J61/125—Selection of substances for gas fillings; Specified operating pressure or temperature having an halogenide as principal component
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0635—Radiation therapy using light characterised by the body area to be irradiated
- A61N2005/0642—Irradiating part of the body at a certain distance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0635—Radiation therapy using light characterised by the body area to be irradiated
- A61N2005/0643—Applicators, probes irradiating specific body areas in close proximity
- A61N2005/0644—Handheld applicators
Definitions
- the invention relates to a radiation arrangement for therapeutic purposes, in particular for the acute or chronic treatment of completely or partially cell-mediated inflammation of the skin, the connective tissue and the internal organs, viral and other infectious diseases such as HIV or prion infections, fungal infections of the skin and mucous membranes, bacterial diseases the skin and mucous membranes as well as hand and anal eczema.
- UV-A1 therapy 340-400 nm
- Chemo-phototherapy as a generic term generally includes the use of optical radiation to achieve therapeutic effects.
- a subfield of chemo-phototherapy is the so-called photodynamic therapy PDT.
- Two main areas of application for PDT are cancer treatment and the treatment of completely or partially cell-mediated skin inflammation.
- a common feature of PDT is the generation of reactive oxygen species.
- the optical radiation stimulates dye molecules administered internally or externally, which are then converted into an excited state. Through interaction with existing oxygen molecules, reactive oxygen species are formed through energy transfer, which then damage or even destroy the cell.
- the main application is tumor treatment of internal organs.
- the optical radiation of a laser is guided endoscopically to the tumor via a glass fiber and the tumor is irradiated selectively.
- photosensitizers become the patient injected.
- the problem arises that the tumor tissue has a poorer blood supply, so that the oxygen content is also very low, but this also limits the conversion into reactive oxygen species. Therefore, in the treatment of tumors of internal organs with PDT it is known to supply the patient with increased oxygen in an inspiratory manner, so that
- Oxygen content in the tumor tissue is increased and reactive oxygen species can be formed. Because of the increased oxygen consumption, it is known to operate the radiation source in pulse mode, so that oxygen can diffuse in the pulse pauses.
- the second area of application in cancer therapy with PDT is the treatment of external tumors such as skin cancer in particular, where additional oxygen is not required due to the presence of oxygen in the area.
- the maximum concentration of endogenous photosensitizers is several orders of magnitude below the concentration that can be achieved after topical and / or systemic application.
- the above-mentioned good blood circulation in connection with the low sensitizer concentration meant that the photo / oxygen therapy in the cell-mediated diseases has come.
- the PDT method mainly used in the treatment of completely or partially cell-mediated skin diseases is the high-dose UV-A1 therapy in the wavelength range from 340-400 nm.
- UV-A1 therapy remains ineffective in approx. 20 - 30% of the treated patients.
- the absorption band of the porphyrins is 630 nm with a penetration depth of 4 mm, which is best suited and also used for photodynamic follicle treatment.
- Acne treatment known which comprises at least a narrow-band spectrum in the range of 405 - 440 nm.
- Spectral ranges are the wavelength intervals from 610 - 670 nm or 520 - 550 nm.
- the irradiance is between 10 - 500 mW / cm 2 .
- EP 0 565 331 B1 discloses a device for treating vascular diseases in an area of the skin, comprising a housing with an incoherent light source, mounted in the housing and suitable for producing pulsed light for the treatment and an opening in the housing which determines an outgoing light beam which is transmitted to the skin treatment area without passing through an optical fiber cable and which has a wider radiation area than devices with optical fiber cables, the
- the device includes a low frequency filter to cut out the visible and ultraviolet parts of the spectrum and the incoherent light source produces an output light beam with wavelengths in the range between 300 and 1000 nm.
- the light source is electrically connected to a variable pulse width generator circuit to provide a controlled time pulse with a width between 1 and 10 ms, the emerging light beam on the skin producing an energy density between 30 and 100 J / cm 2 , so that the emerging light beam after passing through the above-mentioned, low-frequency filter can penetrate into the skin as deeply as desired without burning the skin in order to heat a blood vessel located under the skin and within the skin treatment area and to cause blood coagulation in the blood vessel.
- US Pat. No. 5,964,749 discloses an irradiation arrangement for skin tightening, comprising an irradiation source which emits pulsed light in the wavelength range from 600 to 1200 nm, as a result of which heat is coupled into the tissue below the necrosis threshold and the collagen of the skin is thereby shrunk.
- the pulse energies are of the order of 1 J / cm 2 .
- the radiation peaks of the pulses have an irradiance of 100-1000 W / cm 2 .
- the preferred total energy administered during a treatment is given as 100 J / cm 2 .
- an irradiation arrangement for skin tightening comprising an irradiation source which emits pulsed light in the wavelength interval 500-850 nm, the pulse energy being less than 5 J / cm 2 .
- WO 00/28575 discloses a generic radiation arrangement for therapeutic and cosmetic purposes for the treatment of primarily T-cell-mediated skin diseases, in particular atopic dermatitis, cutaneous T-cell lymphoma, Lieber ruber, alopecia areata, systemic lupus erythermatodes and psoriasis , the
- Irradiation device comprises at least one optical radiation source, which generates an irradiance of at least 2 mW / cm 2 on a surface to be irradiated in the wavelength interval of 400-440 nm and an irradiance of less than 21% of the irradiance in the wavelength range of 300-400 nm 400-440 nm.
- the radiation arrangement utilizes the surprising effectiveness of the radiation in the range of 400-440 nm, whereby a radiation arrangement is available for the treatment of primarily T-cell-mediated skin diseases, by means of which skin diseases such as Lieber ruber, which until now have been difficult to treat, can be treated and, on the other hand, due to the treatment of children is made possible by powers of ten lower carcinogenicity compared to UVA.
- skin diseases such as Lieber ruber, which until now have been difficult to treat
- UVA powers of ten lower carcinogenicity compared to UVA.
- patient-specific threshold values for the irradiance for the therapeutic mode of action of the blue light The reason for this is the different content of melanin and / or antioxidants in the skin, so that preferably irradiations of greater than 60 mW / cm 2 or greater than 100 mW / cm 2 are used.
- EP 0 726 083 A2 discloses a therapeutic radiation arrangement for treating cancer cells in the tissue, which has a treatment and a diagnosis mode.
- a broadband flash lamp is used as the radiation source, the spectrum of which is modified by filters depending on the mode.
- the treatment mode emits in the spectral range between 600-1000 or 600-700 nm, the pulses having an energy density between 0.1-20 J / cm 2 .
- the irradiance is between 100-2000 mW / cm 2 .
- the diagnostic mode takes advantage of the fact that cancer cells fluoresce when irradiated with blue light. This fluorescence can then be detected and evaluated using suitable optics.
- the tissue to be examined is irradiated with pulses in the spectral range between 350-500 nm, with a peak at 400 nm.
- the pulse frequency is between 0.02-2 Hz with an effective pulse length between 0.1-1000 ms.
- the light is coupled into a quartz rod or an optical waveguide with an energy density between 0.02-4 J / cm 2 .
- the area to be diagnosed depends on the distance of the quartz rod or the optical waveguide from the skin surface. Due to the incoherence of the radiation, only a fraction of the radiation energy can be coupled into the optical waveguide. The majority of the energy can be coupled into the quartz rod, but the beam widens extremely when it emerges.
- the energy density on the treatment area is reduced by a factor of 500.
- such distances are necessary in order to observe the fluorescence with the optics, which is clear in the US -6, 021, 344.
- the energy density on the skin thus drops to 0.04-8 mJ / cm 2 , which is, however, sufficient for diagnostic purposes.
- the invention is therefore based on the technical problem of an irradiation arrangement for the treatment of acute and chronic completely or partially cell-mediated inflammation of the skin and the internal organs, viral and other infectious diseases such as HIV or prion diseases, fungal infections of the skin and mucous membranes, bacterial diseases of the skin and to create the mucous membranes as well as hand and anal eczema, which have an improved therapeutic effectiveness compared to the known radiation arrangements.
- infectious diseases such as HIV or prion diseases, fungal infections of the skin and mucous membranes, bacterial diseases of the skin and to create the mucous membranes as well as hand and anal eczema
- the radiation arrangement comprises at least one
- Irradiation source for the area-wide irradiation of a treatment area, the wavelength of the emitted radiation on the treatment area being greater than 400 nm and comprising at least one spectral component in the wavelength interval of 400-500 nm and the irradiation arrangement comprising means for generating optical pulses on the treatment area, the irradiance per pulse is between 0.5 W / cm 2 - 100 kW / cm 2 , the energy density of an emitted optical pulse being between 0.05-10 J / cm 2 .
- the details for the irradiance and the energy density relate to the area to be irradiated, although the irradiation arrangement can be placed directly on the surface.
- an area of radiation is understood to be greater than 0.1 cm 2 .
- the statement greater than 400 nm means that less than 7% of the total optical power is emitted in the UV range, whereas at least 30% of the optical power is emitted in the wavelength interval of 400-500 nm.
- the proportions in the UVC and UVB range are negligibly small in the range below 0.1% of the total output, so that the entire remaining UV component is in the UVA1 and UVA2 range, whereby the ratio of which is approximately 1/10, ie the majority of the remaining UV radiation is in the UVA1 range between 340-400 nm. More preferably, the UV component makes up less than 3.5-5% of the total optical power and the range between 400-500 nm more than 40% of the total optical power.
- the ablation threshold sought in EP 0 565 331 B1 is not reached.
- Ablation ie tissue evaporation occurs whenever an energy> 2500 J / cm 3 is deposited in the tissue within a time that does not allow a significant heat exchange with adjacent layers. Due to the temporal modulation by the pulse generation, the exposure time below the thermal Relaxation time of the upper skin layer is, there is a very strong heating of the upper skin layer, but this can be easily removed.
- Light in the wavelength range 400-500 nm has a half-maximum penetration depth of approx. 200 ⁇ m.
- the estimated thermal relaxation time for a structure with a diameter of 200 ⁇ m is approx. 20 ms. This means that if the light beam stays ⁇ 20 ms, only the upper layers of the skin are warmed up without causing a deep deposition of the energy.
- Irradiation arrangement also suitable for wound disinfection after burns or for treatment of venous ulcers on the lower leg. So far, these have been treated with UV light, although there is often a short-term improvement. However, complications often arise in long-term wound healing. The reason for the short-term success is probably the germicidal effect of UV light, whereas the complications are caused by irreparable cell damage.
- UV-free, time-modulated irradiation by the optical pulses preferably in the spectral range from 400-500 nm, more preferably in the range from 40-480 nm and even more preferably in the range 400-420 nm, occurs in all cells initially an oxidative damage, which is, however, easily repairable by eukaryotic cells because of the FPG endonucleotidases present there. Prokaryotes such as staphylococci or streptococci are much more sensitive to such damage due to the lack of these enzymes and can therefore be selectively killed.
- the radiation arrangement is also suitable for the treatment of acne and acne scars. The activation of the body's own collagen-degrading enzymes causes the scar to flatten out.
- the pulses can be generated either by a pulsed radiation source and / or by a relative movement of the radiation source to the surface to be treated.
- the effective pulse lengths are preferably between 1 ⁇ s and 500 ms. This relatively wide range is due to the fact that the preferred effective pulse lengths for pulsed radiation sources and relatively moving ones
- Irradiation sources in the form of a scanner are different. It should be noted that the scanner is preferably used to treat large-scale skin diseases.
- the effective pulse lengths for the flash lamps are preferably between 1 ⁇ s and 50 ms, particularly preferably between 10 ⁇ s and 10 ms and further preferably between 100-600 ⁇ s, the pulse on and off times being asymmetrical.
- the effective pulse lengths are preferably between 1 ms and 500 ms, further preferably between 20-100 ms.
- the effective pulse length is understood to mean the time that lies between reaching 50% of the maximum output and falling to 50% of the maximum output.
- the longer pulse time-outs in relation to the effective pulse length serve in particular for the post-diffusion of
- the ratio of pulse length to pulse timeout is preferably between 3 and 3000 for the scanner and between 100 and for the flash lamp 100,000. Another effect is the thermal cooling of the irradiated area during the pulse breaks, so that no necrosis occurs.
- the frequency at which the radiation source is pulsed is between 0.01-100 Hz, more preferably between 0.05-50 Hz and even more preferably between 0.3-3 Hz, with lower effective being higher at higher frequencies Pulse lengths and smaller pulse energies can be used.
- a longer dark phase of several seconds to minutes is preferably inserted after a pulse sequence of, for example, 100-500 pulses, before a pulse sequence is generated again.
- a pulse sequence of, for example, 100-500 pulses
- applications are also conceivable where only one pulse is administered at a time and then the radiation arrangement is switched off again for a longer time.
- the breaks can range from one to several hours.
- the radiation arrangement can be permanently assigned to the patient, for example in the form of a belt, a radiation blanket or a light bed, which then receives an optical pulse every 5 minutes, for example. During these long breaks, thermal problems or the post-diffusion of oxygen are negligible.
- the effective pulse lengths depend on whether a pulsed radiation source or a relatively moving radiation source is used, the preferred irradiance levels or power densities per pulse are different.
- Irradiance per pulse between 1 W / cm 2 -100 kW / cm 2 , preferably between 50 W / cm 2 -50 kW / cm 2 , more preferably between 500 W / cm 2 - 10 kW / cm 2 and particularly preferably between 1 kW / cm 2 -5 kW / cm 2 .
- the energy density per pulse is between 50 mJ / cm 2 -10J / cm 2 , preferably between 100 mJ / cm 2 -5J / cm 2 and particularly preferably between 300 mJ / cm 2 - 3J / cm 2 .
- the irradiance per pulse is between 500 mW / cm 2 -500W / cm 2 , preferably between 1-300 W / cm 2 and particularly preferably between 50-200 W / cm 2 .
- the energy density per pulse is between 50 mJ / cm 2 -10J / cm 2 , preferably between 100-5000 mJ / cm 2 and particularly preferably between 150-2000 mJ / cm 2 .
- the higher energy densities between 1-10 J / cm2 are preferably used for the treatment of very serious diseases, whereby there is accordingly the problem of adequate cooling of the area to be irradiated.
- the average cw irradiance of an optical pulse is preferably between 1 mW / cm 2 and 10 W / cm 2 , more preferably between 5- 2000 mW / cm 2 and particularly preferably between 8-800 mW / cm 2 .
- the mean cw irradiance is understood to mean the value that would result if the irradiance of a pulse were distributed evenly over the full period.
- the radiation source is as
- Xe flash lamp which is assigned a device for suppressing and / or transforming the undesired spectral components into the desired spectral range.
- These commercially available Xe flash lamps are very inexpensive and emit with a sufficient power density in the desired spectral range between 400-500 nm.
- reference is made, for example, to US Pat are there because the ablation energy is deliberately exceeded.
- the Xe flash lamps are more or less comparable in spectrum to a black body, which is why they typically emit from 200 - 2000 nm.
- the undesired spectral ranges can be filtered out using known commercial filters.
- gallium, indium and / or their halides are filled into the Xe flash lamp in a preferred embodiment.
- the Xe flash lamp can also be doped with mercury, mercury iodide or amalgam in order to increase the efficiency in the blue range.
- mercury, mercury iodide or amalgam in order to increase the efficiency in the blue range.
- Another possible radiation source is a gallium iodide mercury discharge lamp pulsed in the overload range.
- Overload is understood here when the maximum discharge current is at least 3-1000 times the nominal lamp current, the pulse discharge current preferably being between 15-1500 A / cm 2 cross-sectional area of the
- Discharge vessel is.
- Commercially available cw-operated metal vapor-doped mercury halide lamps are described, for example, in US Pat. Nos. 3,521,111; US 3,540,789 and WO 96/13851.
- Lamp geometry the lamp power of 20 W and the voltage drop of 55 V, a lamp current of 8 A / cm 2 cross-sectional area of the discharge vessel corresponds to the maximum sensible lamp load, since there is already an inversion in the area of indium resonance. A further increase in the current density would increase the inversion until erasure.
- gallium-doped medium or high-pressure mercury iodide lamps do not show any broadening or even inversion of the gallium resonance lines at 403 and 417 nm, even with a 100-1000-fold overload.
- a gallium iodide-doped mercury discharge lamp operated under nominal load with a discharge current of 1.5 A / cm 2 cross-sectional area of the discharge vessel could be operated in pulse mode up to 1000 A / cm 2 cross-sectional area of the discharge vessel without the gallium resonance lines weakening or frequency inversion.
- the metallic gallium has a boiling point of approx. 2200 ° C, so that the relevant gallium vapor pressure can probably be neglected even under impulse conditions.
- the mercury iodide decomposes into mercury and iodine. Under the discharge conditions, the iodine combines with the gallium in the form of the unstable compound Gal 3 .
- Gallium iodide shows a strong increase in vapor pressure even at low temperatures. The lack of inversion of the gallium resonance line could now be explained by the fact that the gallium iodide only behaves stable up to a certain pressure and that when the pressure increases there is a massive, presumably kinetically extremely rapid disintegration of the compound. As a result, a relatively constant gallium vapor pressure occurs despite increasing high temperatures during the pulse. So that carries did not condense gallium to discharge or possible self-absorption.
- the unexpected effect could therefore be related to a paradoxical constancy of the gallium vapor pressure over a temperature range of 200 to almost 2200 ° C.
- Mercury iodide breaks down early into mercury and iodine, making the iodine a gallium compound
- the gallium resonance has an excitation due to the short-wave mercury electron transitions which increases in proportion to the energy fed in. Due to the relative constancy of the gallium vapor pressure, almost all of this energy can be emitted as a resonance line spectrum.
- a modulated lamp can therefore be operated with an increased base load, since the supply of the energy supplied is only considerably more efficient than with a lamp in normal operation only because of the temperature increase. It turned out that a 1 kW lamp can be operated with a continuous load of approx. 2-20 kW.
- Spectral measurements have shown that in a 1000 W cw operation gallium-doped mercury iodide lamp approx. 400 mW / m 2 in the spectral range between 400-440 nm hit the skin. This irradiance can be reduced to an average irradiance of approx.
- the ratio of the pulse lengths is preferably in the range between 3 and 300. This simple pulse light source in the spectral range from 320-540 nm is also for other technical ones
- the ratio of gallium or gallium additive to mercury should preferably be between 1:10 to 1: 100. In the power range of 400 W, a mixing ratio of 1-5 mg gallium iodide to 44 mg mercury is preferably used.
- Another typical lamp consists of a cylindrical quartz tube with a diameter of 13.5 mm and a volume of the discharge vessel of 20 cm 3 . The distance between the electrodes is approx. 14 cm. Such a lamp is filled with 20 mg Hg, 3 mg mercury iodide, 1 mg gallium and argon at a pressure of 3.57 mmHg.
- the UV components can also be transformed into the desired spectral range.
- Films made of silicone elastomers or fluoropolymers, in particular Teflon, with inorganic phosphors have proven particularly useful.
- the silicone elastomers are preferably produced by addition crosslinking, so that no volatile constituents, such as water, come into contact with the inorganic phosphors.
- the silicone elastomer is preferably produced by a mixture of a hydroxylpolydiorganosiloxane with an organohydrogensiloxane, the phosphors being mixed in and then a chemical reaction using a
- the phosphor film preferably has a thickness of 10-800 ⁇ m, the areal density of the phosphor particles preferably being between 1-20 mg / cm 2 and a grain size of 5-15 ⁇ m.
- the UVC-transparent carrier can also be designed as a silicone rubber, which is without heat and
- the cooling device can be designed as an air blower or as a water bath in which the film lies.
- Irradiation source operated in a Simmer, whereby the achievable edge steepness of the pulses can be increased.
- the generation of pulses of the emitted radiation can be implemented by a device by means of which the surface to be irradiated can be moved relative to the radiation source.
- a device by means of which the surface to be irradiated can be moved relative to the radiation source.
- an X or X-Y scanning table is used, by means of which the patient is moved back and forth under the radiation source that can be operated in cw mode.
- all radiation sources which preferably emit in the blue region, such as, for example, blue-emitting LEDs or corresponding gas discharge lamps which preferably contain gallium, indium or their halides, are suitable as the radiation source for cw operation.
- the scan speed it is also important to ensure that the ablation threshold is not exceeded either. For this purpose, for example, a focal line with a thickness of several millimeters is generated, which then has a
- Pulse lengths for an area to be irradiated can be further reduced, which is particularly advantageous with regard to thermal relaxation.
- the radiation arrangement is designed with a device for cooling the area to be irradiated in order to prevent necrosis of the irradiated cells.
- a device for cooling the area to be irradiated in order to prevent necrosis of the irradiated cells.
- heating of the cells above 60 ° C must be prevented.
- Type and scope of Cooling depends on which energies are administered in which time sequence. As a rule, simple air cooling with a possibly cooled air flow is completely sufficient. At very high energies, air cooling can be replaced by contact cooling, which is generated, for example, by a cooled sapphire or coolant sprayed directly onto the skin.
- Other options for contact cooling are the use of cooled liquids such as water, oils or alcohol, which extract the heat from the tissue via a membrane made of latex or silicone.
- the coolants must be optically transparent, the heat transfer resistance being as small as possible. The more the skin can be cooled without causing freezing damage, the more energy can be radiated in without exceeding the necrosis threshold of the cells.
- Another advantage of the pulses comes into play here.
- the gradients of the heat input through the optical pulses and the cold supply through the cooling are different in the tissue.
- the gradient of the cold supply is generally flatter, so that freeze damage could occur due to crystallization.
- the pulses cause a shock warming in the range of 100 ⁇ s, so that ice formation is disturbed despite the low temperatures.
- Cooling is preferably carried out synchronously with the introduction of heat, ie the cooling capacity is increased during the pulse. This control can take place, for example, by means of a Peltier element, the temperature of the coolant being reduced from, for example, 4 ° C. during the pulse to - (40-80) ° C.
- the efficiency of the radiation arrangement can be further increased by increasing the oxygen concentration. In addition to the measures described in WO 00/02491, this can also be done very simply by an inspiratory oxygen supply via an oxygen mask.
- the advantage of inspiratory oxygenation is that even deeper tissue areas are increasingly supplied with oxygen through the blood circulation, whereas a gradient from the surface of the skin to the cells must always be taken into account in the case of topical oxygenation.
- the mean penetration depth of the light is strongly dependent on the wavelength, the penetration depth increasing with the wavelength. Therefore, in a preferred embodiment, emitting is additionally carried out in the range from 520 to 550 nm and / or 610 to 670 nm, which can be implemented very easily, for example, by adding appropriate phosphors to the phosphor film.
- the red or yellow component for the irradiation of deeper lying cells is increased at the expense of the blue component.
- the blue component also plays an important role in deeper inflammation, since it kills superficial bacteria that often settle as a result of the inflammation and produce so-called superantigens that are themselves inflammatory.
- the radiation source is preferably formed with a reflector.
- a reflector This can be designed, for example, as a paraboloid or ellipsoid reflector.
- the paraboloid reflector is preferably used when the temporal modulation of the emitted radiation is realized by pulse operation, whereas the ellipsoid reflector is preferably used in the scan operation.
- the beam diameter of the emitted radiation is preferably greater than 4 mm, preferably greater than 10 mm and particularly preferably greater than 40 mm. This takes advantage of the fact that the depth of penetration of the light also depends on the size of the surface to be irradiated. The penetration depth is only very small, in particular in the case of almost punctiform radiation. In the case of extensive radiation, there is an additive overlay of neighboring scattered photons despite the scatter in the upper skin layers. As a result, the resulting penetration depth is significantly greater than with punctiform irradiation with the same area coverage. However, the beam diameter should not be too large either and should therefore not exceed 200 mm, preferably 100 and particularly preferably 60 mm. This is based on the following considerations.
- Chromophores can be excited photochemically over a much longer period than a short pulse.
- the lack of radiation peaks within the radiation area prevents local bleaching or the local substrate deficiency of oxygen.
- a local maximum is formed in the central area of the
- the optimal radiation field since the non-directional scattering of all rays leads to an addition in the central area.
- the optimal radiation field has a diameter> 4 mm and ⁇ 60 mm, because with this large diameter the scattering of the marginal rays no longer contributes to increasing the intensity in the central area.
- the area coverage decreases in proportion to the increase in area, so that no light effect can be measured in the deeper tissue areas.
- the time until the ever larger tissue areas are re-irradiated is shorter and shorter, so that heat dissipation or cooling is made more difficult.
- FIG. 1 shows a cross section through an irradiation arrangement with a pulsable radiation source
- FIG. 2 shows a spectrum of the irradiation source with fluorescent film
- FIG. 3 shows a schematic illustration of an irradiation arrangement with an angular movement of the irradiation source
- 4 shows a schematic representation of an irradiation arrangement with a one-dimensional scan movement
- FIG. 5 shows a schematic representation of an irradiation arrangement with a two-dimensional scan movement
- FIGS. 6a-c show various representations of the penetration depth above the
- FIG. 7 shows the penetration depth over the wavelength
- Fig. 9 curves of the relative irradiance of a gallium-doped mercury iodide lamp in cw mode and pulsed
- Fig. 10 the spectral energy density of a gallium-doped
- FIG. 12 shows a schematic circuit arrangement for the pulse operation of a gallium-doped mercury iodide lamp with two phases of a three-phase network
- FIG. 13 shows an alternative circuit arrangement with a capacitor bank.
- the irradiation arrangement 1 comprises a pulsable radiation source 2, which is preferably designed as an Xe flash lamp.
- the radiation source 2 is arranged in a focal point of a paraboloid reflector 3, which is open on the side facing away from the focal point.
- the exit surface at the open end of the paraboloid reflector 3 is defined by a preferably adjustable diaphragm 4.
- the size of the area to be irradiated can thus be adjusted by means of the adjustable diaphragm 4.
- the radiation source 2 and the paraboloid reflector 3 are arranged in a housing 5.
- the housing 5 is preferably designed with a handpiece 6, by means of which the irradiation arrangement 1 can simply be placed on a surface 7 to be treated.
- a fluorescent film 8 is arranged, which is doped with fluorescent particles.
- the phosphor sheet 8 can also be stretched directly in the area of the radiation source 2 or via the diaphragm 4.
- the fluorescent film 8 is preferably arranged such that it is easy to replace. This simplifies the necessary exchange due to aging processes, but also the flexible use of fluorescent films with different fluorescent particles. Furthermore, if the fluorescent film 8 is arranged externally, it can be easily disinfected.
- the electrical connections and a circuit for generating a variable pulse width are not shown here for reasons of clarity.
- the fluorescent film is a silicone elastomer that is doped with inorganic phosphors that preferentially emit in the blue spectral range of 400-450 nm.
- the fluorescent film almost cuts off the UV range between 280-400 nm and transforms it into the visible blue range of 400-450 nm.
- the energy in the range below 400 nm is less than 4.5% of the total optical power
- the UV radiation is almost exclusively in the range of 340-400 nm and in particular in the range between 370-400 nm. Since this wavelength range has orders of magnitude less photobiological effectiveness than the UVB or UVC range, the international limit values not exceeded for UV exposure.
- ICNIRP IRPA
- Wavelength interval between 400-500 nm is 43.6% and in the wavelength interval between 400-450 nm 28.2% of the optical Overall performance.
- the measurement was carried out using a calibrated CDI spectrometer and 100 ⁇ m UV fiber.
- the Xe flash lamp is clocked at a frequency of 0.01-100 Hz, but the effective pulse lengths are between 10 ⁇ s and 1 ms.
- the energy of the individual pulses is preferably in the range of 0.3-0.8 J / cm 2 .
- the radiation arrangement 1 comprises a patient rest device 9, above which the radiation source 2 is arranged.
- the radiation source 2 is again surrounded by a paraboloid, ellipsoid or a half-cylinder reflector 3.
- the radiation source 2, together with the reflector 3, can be pivoted to the left and at night by the angle ⁇ from the vertical position to the patient rest device 9 by means of a pivoting device (not shown).
- a pivoting device not shown.
- the radiation source can be pulsed again or can also be operated in cw mode.
- the patient rest device 9 can also be pivoted.
- the radiation source 2 is in this case in the form of a line or strip-shaped radiation source 2 and is arranged above the patient rest device 9 on a support 11 such that it can be moved in the direction of the arrow.
- the radiation source 2 can be operated in pulse or cw mode. This scan movement in the direction of the arrow also achieves temporal light modulation for each individual body part.
- the one-dimensional scan movement from FIG. 4 can also be replaced by a two-dimensional scan movement.
- the areal radiation source 2 can also be moved transversely to the patient 10.
- FIG. 6a shows in cross section which power densities can be found in which penetration depth when the light power is irradiated with a beam diameter of 20 mm.
- the power density at a depth of 15 mm is still 0.1 kW / cm 2 .
- the relationships are shown in FIG. 6b when the same total power is coupled into the tissue over a beam diameter of 1 mm. If a square radiation area is assumed, the power density has increased four hundredfold. However, this leads to a huge gradient of the penetrating power density, the power density of 100 kW / cm 2 being so high, in particular directly on the tissue surface, that ablation occurs. However, if the
- Penetration depths can be reached without avoiding ablation on the surface.
- the penetration depth increases continuously from 400 nm to 900 nm, so that, in particular in the treatment of deep-lying cells, it is advantageous to increase the green and red region of the emitted spectrum at the expense of the blue component, even if the absorption of the porphyrins is opposite the blue part is worse.
- FIG. 8a shows a preferred embodiment of a radiation therapy with a pulsable radiation source with a radiation peak of 5 kW / cm 2 .
- a sequence of pulses or flashes is emitted.
- the individual pulse has an effective pulse length t1 between 100-2000 ⁇ s, followed by a pulse duration t2 between 10ms-1000s.
- the effective pulse length t1 is preferably between 100-500 ⁇ s and the pulse time-out t2 between 100 ms- 4 s.
- the number of pulses is preferably between 10 and 10,000, particularly preferably between 100 and 1000.
- the total pulse sequence time t3 results accordingly (t1 + t2) multiplied by the number of pulses.
- This first pulse sequence is followed by a time t4 in which no irradiation takes place, so that oxygen can diffuse again and the tissue can cool down at the same time, which prevents the formation of necrosis.
- the time t4 is preferably chosen between 1 min and 100 min, the longer times being particularly preferred.
- a pulse sequence with the pulse sequence time t3 is then generated again. This is followed by a time t4.
- the total irradiation time t5 is chosen between a few minutes and 2 hours depending on the severity of the disease. After a long break of several hours or 1-3 days, the entire process is then repeated. No additional dye molecules are added internally or externally, so that the process described is not a PDT.
- the situation will be explained in more detail using a still concrete example for the treatment of allergic contact eczema.
- two radiation cycles are carried out per day, with t3 and t4 being chosen to be 5 minutes each, so that a total treatment time of 15 minutes per day results.
- the pulse frequency is 0.5 Hz, so that 150 pulses are applied in a period t3.
- the effective pulse length t1 is 100 ⁇ s with a rise time of approx. 10 ⁇ s.
- the pulse timeout t2 is approx. 2s.
- the radiation peak of the pulses is 0.5 kW / cm 2 , the energy density per pulse being between 0.4-0.5 J / cm 2 depending on the slope. This results in an average cw power of 250 mW / cm 2 .
- the energy density applied per day is therefore 120-150 J / cm 2 . With a total of 2
- the total energy density is 240-300 J / cm 2 , the treatment preferably lasting 4-8 weeks.
- the radiation therapy described was also carried out at a frequency of 0.05 Hz, the values for t1, t3 and t4 and the radiation peak being retained. Due to the tenfold increase in t2, the applied energy density per treatment cycle and the mean cw output decrease by a factor of ten, whereby the results of the treatment results were comparable. This is presumably due to the very slow acid diffusion, so that without an additional supply of oxygen, any increase in the energy density at the same time hardly brings about an additional therapeutic effect.
- FIG. 8b shows the irradiation cycle with an irradiation arrangement according to FIG. 4, the irradiation source being operated in cw mode.
- the radiation peak is 5 W / cm 2 , which is considerably lower than in the pulse mode according to FIG.
- the time t1 corresponds to the time that the radiation source irradiates a certain area during the scanning process due to its areal radiation and is preferably between 0.1 and 0.5 s.
- the time t2 is the time of a complete scanning process minus the time t1. During this time, oxygen can diffuse again and the tissue can cool down.
- t2 is between 1 and 300 seconds, preferably between 2-20 seconds.
- the radiation peaks being between 250 and 500 W / cm 2 .
- the effective pulse length is preferably chosen to be 100 ⁇ s and the radiation source is clocked at 25 Hz, so that t2 results in 40 ms with an irradiation time t3 of 0.2 s.
- the most diverse combinations of the numerical details of the exemplary embodiments according to FIGS. 8a and b are possible. In general, it has been observed that the addition of anti-inflammatory substances such as cortisone is counterproductive.
- the intake of such substances should be avoided completely before the treatment, with the anti-inflammatory substances preferably being discontinued a few days in advance due to the long-term effect. It was also observed that untreated parts of the body healed when small areas were treated. This indicates a local systemic effect of the radiation, which is similar to an immunization in a vaccination.
- the circuit 12 shows a first circuit arrangement for operating a gallium-doped mercury iodide lamp for pulse overload operation.
- the circuit includes a gallium-doped mercury iodide lamp 30, one Ignition rod 31, a current zero continuity detector 32, a pulse generator 33, a first relay K1 and a second relay K2, as well as a starter switch S1 and a pulse switch 34.
- the two relays K1 and K2 are both with a neutral conductor N and a first phase V1 of a three-phase network connected.
- the gallium-doped mercury iodide lamp 30 is connected to a second phase V2 of the three-phase network via an auxiliary contact of the starter switch S1.
- the first phase V1 is connected to the ignition rod 31 via the current-zero continuity detector 32 via a coil arrangement.
- the coils L1 and L2 are connected in series.
- a third coil L3 with a contact K2 associated with the second relay K2 is connected in parallel with this series connection.
- a first associated contact K1.1 of the first relay K1 is connected in parallel with the first coil L1.
- a second associated contact K1.2 of the first relay K1 is connected between the second relay K2 and the pulse switch 34.
- the starter switch S1 is closed, whereby the two associated auxiliary contacts also close.
- contact K1.1 closes and contact K1.2 opens or remains open.
- the first phase V1 of the three-phase network is connected to the ignition rod 31 via the coil L2 via the closed contact K1.1, the coil L2 acting as a series reactor. This switching state is maintained until the gallium-doped mercury iodide lamp 30 has reached its normal operating conditions.
- relay K1 drops out, which is designed, for example, as a switch-on wiper.
- the drop from the relay K1 causes the contact K1.1 to open and the contact K1.2 to close. This activates the relay K2 and simultaneously switches the coil L1 in series with the coil L2, the coil L1 acting as a Simmer coil.
- the pulse switch 34 Since the pulse switch 34 is still open, the contact K2 remains open. In this state, the gallium-doped mercury iodide lamp 30 runs in a Simmer.
- the current zero crossing detector 32 now detects a zero crossing of the Current of the first phase V1 of the three-phase network and signals this to the pulse generator 33. This switches the pulse switch 34 so that the relay K2 is energized and the contact K2 is closed.
- the coil L3 is connected in parallel and the total inductance drops, as a result of which the ignition rod 31 receives an overload pulse.
- the pulse generator 33 opens the pulse switch 34.
- the contact K2 is opened and the gallium-doped mercury iodide lamp 30 is operated in the Simmer again by the series connection of the coils L1 and L2 until the next pulse is triggered by the pulse generator 33.
- FIG. 13 An alternative embodiment with a capacitor bank is shown in FIG. 13, the same elements being provided with the same reference symbols with respect to FIG.
- a triac 35 is arranged between the ignition rod 31 and the gallium-doped mercury iodide lamp 30, the driver 36 of which is controlled by the pulse generator 33.
- the capacitor bank 38 is connected to the electrodes of the gallium-doped mercury iodide lamp 30 via an IGBT 37 or the coil L3, the driver 39 of the IGBT 37 also being controlled by the pulse generator 33.
- the mode of operation is as follows:
- the starter switch S1 is closed again, whereby the contact K1.1 closes and the contact K1.2 opens.
- the gallium-doped mercury iodide lamp 30 is raised to operating conditions via the switched-on triac 35. Then the relay K1 drops out again and the contact K1.1 opens and K1.2 closes.
- the gallium-doped mercury iodide lamp 30 is then operated in the Simmer via the series connection of the coils L1 and L2 and the pulse generator 33 is activated.
- the current-zero crossing detector 32 detects the zero crossing and transmits this information to the pulse generator 33. The latter then controls the drivers 36 and 39 so that the triac 35 blocks and the IGBT 37 conducts.
- the capacitor bank is switched to the gallium-doped mercury iodide lamp 30 and this is separated from the mains voltage.
- the IGBT 37 is blocked and the triac 35 is switched through, so that the lamp 30 again runs in the Simmar via the two coils L1 and L2.
- this generally means inductors.
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002435916A CA2435916A1 (en) | 2001-03-08 | 2002-03-05 | Irradiation device |
DE50214709T DE50214709D1 (de) | 2001-03-08 | 2002-03-05 | |
EP02750510A EP1365840B1 (de) | 2001-03-08 | 2002-03-05 | Bestrahlungsanordnung-für therapeutische zwecke |
AT02750510T ATE484317T1 (de) | 2001-03-08 | 2002-03-05 | Bestrahlungsanordnung-für therapeutische zwecke |
JP2002571155A JP4167901B2 (ja) | 2001-03-08 | 2002-03-05 | 治療用目的の照射装置 |
DE10290911T DE10290911D2 (de) | 2001-03-08 | 2002-03-05 | Bestrahlungsanordnung für therapeutische Zwecke |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE20109899 | 2001-03-08 | ||
DE20109899.7 | 2001-03-08 | ||
DE10123926A DE10123926A1 (de) | 2001-03-08 | 2001-05-10 | Bestrahlungsanordnung |
DE10123926.2 | 2001-05-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002072200A1 true WO2002072200A1 (de) | 2002-09-19 |
Family
ID=26009318
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE2002/000778 WO2002072200A1 (de) | 2001-03-08 | 2002-03-05 | Bestrahlungsanordnung_für therapeutische zwecke |
Country Status (7)
Country | Link |
---|---|
US (3) | US6902563B2 (de) |
EP (3) | EP1365839B1 (de) |
JP (1) | JP4167901B2 (de) |
AT (2) | ATE406192T1 (de) |
CA (1) | CA2435916A1 (de) |
DE (4) | DE10123926A1 (de) |
WO (1) | WO2002072200A1 (de) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005525193A (ja) * | 2002-05-15 | 2005-08-25 | ロエイ・メディカル・テクノロジーズ・リミテッド | 生体組織の正確な側部部分除去手術のための作業器具及びその使用法 |
WO2007029151A3 (en) * | 2005-09-06 | 2007-06-07 | Koninkl Philips Electronics Nv | Uv lamp for treatment of the skin |
EP2236150A4 (de) * | 2007-12-21 | 2012-02-29 | Asac Compania De Biotecnologia E Investigacion Sa | Verfahren zur erhöhung der therapeutischen wirksamkeit von curcuminoiden und analoga |
WO2017121656A1 (de) * | 2016-01-15 | 2017-07-20 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Flexible, umweltfreundliche lampenvorrichtung mit gasentladungslampe und verwendungen hiervon |
IT202100002870A1 (it) * | 2021-02-10 | 2022-08-10 | Giardinagroup S R L | Metodo e apparato per la reticolazione di una vernice |
Families Citing this family (120)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8182473B2 (en) | 1999-01-08 | 2012-05-22 | Palomar Medical Technologies | Cooling system for a photocosmetic device |
US6273884B1 (en) | 1997-05-15 | 2001-08-14 | Palomar Medical Technologies, Inc. | Method and apparatus for dermatology treatment |
US6517532B1 (en) | 1997-05-15 | 2003-02-11 | Palomar Medical Technologies, Inc. | Light energy delivery head |
AU3450799A (en) | 1998-03-12 | 1999-09-27 | Palomar Medical Technologies, Inc. | System for electromagnetic radiation of the skin |
US7494488B2 (en) * | 1998-05-28 | 2009-02-24 | Pearl Technology Holdings, Llc | Facial tissue strengthening and tightening device and methods |
US20060212025A1 (en) * | 1998-11-30 | 2006-09-21 | Light Bioscience, Llc | Method and apparatus for acne treatment |
US6887260B1 (en) | 1998-11-30 | 2005-05-03 | Light Bioscience, Llc | Method and apparatus for acne treatment |
US6283956B1 (en) | 1998-11-30 | 2001-09-04 | David H. McDaniels | Reduction, elimination, or stimulation of hair growth |
US20080091179A1 (en) * | 1999-12-10 | 2008-04-17 | Candela Corporation | Compact, handheld device for home-based acne treatment |
US7351252B2 (en) * | 2002-06-19 | 2008-04-01 | Palomar Medical Technologies, Inc. | Method and apparatus for photothermal treatment of tissue at depth |
HU224941B1 (en) * | 2001-08-10 | 2006-04-28 | Bgi Innovacios Kft | Phototerapy apparatus |
US7303578B2 (en) | 2001-11-01 | 2007-12-04 | Photothera, Inc. | Device and method for providing phototherapy to the brain |
US8308784B2 (en) | 2006-08-24 | 2012-11-13 | Jackson Streeter | Low level light therapy for enhancement of neurologic function of a patient affected by Parkinson's disease |
US7534255B1 (en) | 2003-01-24 | 2009-05-19 | Photothera, Inc | Low level light therapy for enhancement of neurologic function |
US7494502B2 (en) * | 2002-02-11 | 2009-02-24 | Keraderm, Llc | Alteration of the skin and nail for the prevention and treatment of skin and nail infections |
US6960201B2 (en) * | 2002-02-11 | 2005-11-01 | Quanticum, Llc | Method for the prevention and treatment of skin and nail infections |
AUPS051002A0 (en) * | 2002-02-14 | 2002-03-07 | Riancorp Pty Ltd | Low level laser therapy method and means |
US20040073277A1 (en) * | 2002-04-05 | 2004-04-15 | Geronemus Roy G. | High fluence rate activation of photosensitizers for dermatological applications |
KR20050026404A (ko) | 2002-06-19 | 2005-03-15 | 팔로마 메디칼 테크놀로지스, 인코포레이티드 | 깊이로 조직을 광열 치료하기 위한 방법 및 장치 |
US20040034397A1 (en) * | 2002-08-14 | 2004-02-19 | Lin J. T. | Method and apparatus for treating skin disorders using a short pulsed incoherent light |
US20040156743A1 (en) * | 2002-08-28 | 2004-08-12 | Eric Bornstein | Near infrared microbial elimination laser system |
US20080131968A1 (en) * | 2002-08-28 | 2008-06-05 | Nomir Medical Technologies, Inc. | Near-infrared electromagnetic modification of cellular steady-state membrane potentials |
US8506979B2 (en) | 2002-08-28 | 2013-08-13 | Nomir Medical Technologies, Inc. | Near-infrared electromagnetic modification of cellular steady-state membrane potentials |
US20040126272A1 (en) * | 2002-08-28 | 2004-07-01 | Eric Bornstein | Near infrared microbial elimination laser system |
US7713294B2 (en) | 2002-08-28 | 2010-05-11 | Nomir Medical Technologies, Inc. | Near infrared microbial elimination laser systems (NIMEL) |
EP2522294A2 (de) | 2002-10-23 | 2012-11-14 | Palomar Medical Technologies, Inc. | Photobehandlungsvorrichtung zur Verwendung mit Kühlmitteln und topischen Substanzen |
US7255560B2 (en) * | 2002-12-02 | 2007-08-14 | Nomir Medical Technologies, Inc. | Laser augmented periodontal scaling instruments |
GB2397528B (en) * | 2003-01-24 | 2005-07-13 | Enfis Ltd | Method and device for treatment of skin conditions |
EP1596745B1 (de) * | 2003-02-25 | 2016-02-17 | Tria Beauty, Inc. | Abgeschlossenes dermatologisches behandlungs gerät auf diodenlaser-basis |
WO2004075681A2 (en) * | 2003-02-25 | 2004-09-10 | Spectragenics, Inc. | Self-contained, eye-safe hair-regrowth-inhibition apparatus and method |
US7981111B2 (en) | 2003-02-25 | 2011-07-19 | Tria Beauty, Inc. | Method and apparatus for the treatment of benign pigmented lesions |
US7413567B2 (en) * | 2003-02-25 | 2008-08-19 | Spectragenics, Inc. | Optical sensor and method for identifying the presence of skin |
ES2570989T3 (es) * | 2003-02-25 | 2016-05-23 | Tria Beauty Inc | Aparato de tratamiento dermatológico seguro para el ojo |
JP2006518614A (ja) * | 2003-02-25 | 2006-08-17 | スペクトラジェニクス インコーポレイテッド | ニキビ処置装置および方法 |
EP2604216B1 (de) | 2003-02-25 | 2018-08-22 | Tria Beauty, Inc. | In sich geschlossene Vorrichtung zur dermatologischen Behandlung auf Diodenlaserbasis |
US20040176824A1 (en) * | 2003-03-04 | 2004-09-09 | Weckwerth Mark V. | Method and apparatus for the repigmentation of human skin |
JP4435149B2 (ja) * | 2003-03-06 | 2010-03-17 | トリア ビューティ インコーポレイテッド | 皮膚接触感知装置 |
US20050055070A1 (en) * | 2003-03-07 | 2005-03-10 | Gareth Jones | Method and device for treatment of skin conditions |
CA2531099A1 (en) | 2003-04-10 | 2004-10-28 | Light Bioscience, Llc | Photomodulation methods and devices for regulating cell proliferation and gene expression |
US7470124B2 (en) * | 2003-05-08 | 2008-12-30 | Nomir Medical Technologies, Inc. | Instrument for delivery of optical energy to the dental root canal system for hidden bacterial and live biofilm thermolysis |
WO2004105859A2 (en) * | 2003-05-24 | 2004-12-09 | Ledeep, Llc | Skin tanning and light therapy system and method |
JP4266706B2 (ja) * | 2003-05-29 | 2009-05-20 | Necライティング株式会社 | ナローバンドuv−b光線治療器 |
US7291140B2 (en) * | 2003-07-18 | 2007-11-06 | Cutera, Inc. | System and method for low average power dermatologic light treatment device |
CA2533129A1 (en) | 2003-07-31 | 2005-02-10 | Light Bioscience, Llc | System and method for the photodynamic treatment of burns, wounds, and related skin disorders |
AU2004266722A1 (en) * | 2003-08-19 | 2005-03-03 | The General Hospital Corporation | Method and apparatus for reducing the appearance of skin markings |
US20080172045A1 (en) * | 2003-10-24 | 2008-07-17 | Shanks Steven C | Acne treatment device |
DE10351706A1 (de) | 2003-11-03 | 2005-06-16 | Plasma Photonics Gmbh | Strahlungskonverter und den Konverter enthaltende Bestrahlungsanordnung |
US7914523B2 (en) * | 2004-02-06 | 2011-03-29 | Clinique Dr Daniel Barolet Inc. | Method for the treatment of mammalian tissues |
US20050256553A1 (en) * | 2004-02-09 | 2005-11-17 | John Strisower | Method and apparatus for the treatment of respiratory and other infections using ultraviolet germicidal irradiation |
US20060009749A1 (en) * | 2004-02-19 | 2006-01-12 | Weckwerth Mark V | Efficient diffuse light source assembly and method |
US8777935B2 (en) | 2004-02-25 | 2014-07-15 | Tria Beauty, Inc. | Optical sensor and method for identifying the presence of skin |
US7921853B2 (en) * | 2004-03-09 | 2011-04-12 | Ledeep Llc | Phototherapy method for treating psoriasis |
AU2005231443B2 (en) | 2004-04-01 | 2012-02-23 | The General Hospital Corporation | Method and apparatus for dermatological treatment and tissue reshaping |
EP1740144A4 (de) * | 2004-04-12 | 2008-07-23 | Ledeep Llc | Fototherapiesysteme und verfahren |
JP4024227B2 (ja) * | 2004-04-14 | 2007-12-19 | 昇 堀口 | 電位治療器と電位治療器用波形整形器 |
GB2416699B (en) * | 2004-08-05 | 2010-04-14 | Photo Therapeutics Ltd | Skin rejuvenation |
US8277495B2 (en) | 2005-01-13 | 2012-10-02 | Candela Corporation | Method and apparatus for treating a diseased nail |
US8109981B2 (en) * | 2005-01-25 | 2012-02-07 | Valam Corporation | Optical therapies and devices |
US7856985B2 (en) | 2005-04-22 | 2010-12-28 | Cynosure, Inc. | Method of treatment body tissue using a non-uniform laser beam |
EP1733691A1 (de) * | 2005-06-14 | 2006-12-20 | Koninklijke Philips Electronics N.V. | Gerät zur kosmetischen Hautverjüngungsbehandlung |
JP4431527B2 (ja) * | 2005-07-12 | 2010-03-17 | 株式会社フューテック | 美容機器 |
JP2009502258A (ja) * | 2005-07-21 | 2009-01-29 | ノミール・メディカル・テクノロジーズ・インコーポレーテッド | 標的部位の生物学的汚染物質のレベルを下げる方法 |
CA2622560A1 (en) | 2005-09-15 | 2007-03-29 | Palomar Medical Technologies, Inc. | Skin optical characterization device |
US20070135876A1 (en) * | 2005-12-08 | 2007-06-14 | Weber Paul J | Acne and skin defect treatment via non-radiofrequency electrical current controlled power delivery device and methods |
WO2007087374A2 (en) * | 2006-01-24 | 2007-08-02 | Nomir Medical Technologies, Inc. | Optical method and device for modulation of biochemical processes in adipose tissue |
US10357662B2 (en) | 2009-02-19 | 2019-07-23 | Pthera LLC | Apparatus and method for irradiating a surface with light |
US20090254154A1 (en) | 2008-03-18 | 2009-10-08 | Luis De Taboada | Method and apparatus for irradiating a surface with pulsed light |
US7575589B2 (en) | 2006-01-30 | 2009-08-18 | Photothera, Inc. | Light-emitting device and method for providing phototherapy to the brain |
WO2007106856A2 (en) * | 2006-03-14 | 2007-09-20 | Allux Medical, Inc. | Phototherapy device and method of providing phototherapy to a body surface |
JP5010327B2 (ja) | 2006-06-26 | 2012-08-29 | パナソニック株式会社 | 毛成長調節装置 |
US7586957B2 (en) | 2006-08-02 | 2009-09-08 | Cynosure, Inc | Picosecond laser apparatus and methods for its operation and use |
US20080055755A1 (en) * | 2006-08-31 | 2008-03-06 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Electromagnetic device and method |
US20080058905A1 (en) * | 2006-09-01 | 2008-03-06 | Wagner Darrell O | Method and apparatus utilizing light as therapy for fungal infection |
JPWO2008062655A1 (ja) * | 2006-11-21 | 2010-03-04 | コニカミノルタオプト株式会社 | 金型の製造方法及び投影光学系用反射ミラー |
WO2008106576A1 (en) * | 2007-02-28 | 2008-09-04 | Keraderm Llc | Phototherapy treatment and device to improve the appearance of nails and skin |
EP2194899A4 (de) * | 2007-08-08 | 2012-11-28 | Tria Beauty Inc | Kapazitives messverfahren und vorrichtung zum nachweis von haut |
EP2268198A4 (de) | 2008-04-25 | 2014-10-15 | Tria Beauty Inc | Optischer sensor und verfahren zur erkennung des vorhandenseins von haut und hautpigmentation |
US8348938B2 (en) | 2008-05-06 | 2013-01-08 | Old Dominian University Research Foundation | Apparatus, systems and methods for treating a human tissue condition |
US7848035B2 (en) | 2008-09-18 | 2010-12-07 | Photothera, Inc. | Single-use lens assembly |
JP5204606B2 (ja) * | 2008-09-30 | 2013-06-05 | パナソニック株式会社 | 発毛調節光照射装置 |
FR2936714B1 (fr) * | 2008-10-02 | 2016-06-24 | Oreal | Procede de traitement cosmetique et ensemble pour la mise en oeuvre d'un tel procede |
US20100100083A1 (en) * | 2008-10-22 | 2010-04-22 | Scott Lundahl | Method of treatment for dermatologic disorders |
US20120046653A1 (en) * | 2009-03-05 | 2012-02-23 | Cynosure, Inc. | Pulsed therapeutic light system and method |
EP2229980B1 (de) * | 2009-03-16 | 2015-08-12 | Nuvolase, Inc. | Behandlung mikrobiologischer Krankheitserreger in einem Zehennagel mit antimikrobiellem Licht |
WO2010142013A1 (en) * | 2009-06-08 | 2010-12-16 | Biolux Research Limited | Method and device for accelerating orthodontic tooth movement |
US8814922B2 (en) * | 2009-07-22 | 2014-08-26 | New Star Lasers, Inc. | Method for treatment of fingernail and toenail microbial infections using infrared laser heating and low pressure |
US9919168B2 (en) | 2009-07-23 | 2018-03-20 | Palomar Medical Technologies, Inc. | Method for improvement of cellulite appearance |
JP5702529B2 (ja) * | 2009-10-26 | 2015-04-15 | 良典 丸中 | 医療用光照射装置 |
US10780295B2 (en) | 2010-02-05 | 2020-09-22 | Wisconsin Alumni Research Foundation | Method for treating multiple sclerosis |
EP2531259A4 (de) * | 2010-02-05 | 2013-10-16 | Wisconsin Alumni Res Found | Verfahren zur behandlung von multipler sklerose |
US20130344454A1 (en) * | 2010-11-10 | 2013-12-26 | Günther Nath | Optical Irradiation Appliance for Dermatology and Beauty Care |
US9093258B2 (en) | 2011-06-08 | 2015-07-28 | Xenex Disinfection Services, Llc | Ultraviolet discharge lamp apparatuses having optical filters which attenuate visible light |
US9165756B2 (en) | 2011-06-08 | 2015-10-20 | Xenex Disinfection Services, Llc | Ultraviolet discharge lamp apparatuses with one or more reflectors |
KR102183581B1 (ko) | 2012-04-18 | 2020-11-27 | 싸이노슈어, 엘엘씨 | 피코초 레이저 장치 및 그를 사용한 표적 조직의 치료 방법 |
USD722383S1 (en) | 2012-05-01 | 2015-02-10 | Carol Cole Company | Skin clearing and toning device |
EP2973894A2 (de) | 2013-03-15 | 2016-01-20 | Cynosure, Inc. | Optische picosekunden-strahlungssysteme und verfahren zur verwendung |
DE202014011570U1 (de) | 2013-10-22 | 2023-04-04 | Biolux Research Holdings, Inc. | Intraorale Lichttherapiegeräte |
USD738517S1 (en) * | 2013-10-30 | 2015-09-08 | Trophy Skin, Inc. | Skin toning device |
AU2015210594B2 (en) | 2014-02-03 | 2019-10-31 | Zerigo Health, Inc. | Systems and methods for phototherapy |
USD739541S1 (en) | 2014-05-12 | 2015-09-22 | Carol Cole Company | Skin clearing and toning device |
WO2016011233A1 (en) * | 2014-07-16 | 2016-01-21 | LiteProducts LLC | Device and method for inactivating pathogens using visible light |
CN106998764B (zh) | 2014-09-18 | 2021-07-30 | Xenex消毒服务股份有限公司 | 利用具有经调制功率通量的脉冲光和在脉冲之间具有可见光补偿的光系统进行房间和区域消毒 |
EP3206721A1 (de) | 2014-10-15 | 2017-08-23 | Xenex Disinfection Services, LLC | System und verfahren zur desinfektion vor dem ausziehen |
US10039600B2 (en) * | 2015-02-03 | 2018-08-07 | L'oreal | Apparatus and method for skin treatment using pulsed light |
USD752237S1 (en) | 2015-03-03 | 2016-03-22 | Carol Cole Company | Skin toning device |
KR20170135913A (ko) | 2015-04-10 | 2017-12-08 | 클래러파이 메디칼, 인크. | 광선치료 광 엔진 |
WO2017019455A2 (en) | 2015-07-24 | 2017-02-02 | Skylit Corporation | Systems and methods for phototherapy control |
US10632324B2 (en) | 2017-04-27 | 2020-04-28 | 9127-4910 Quebec Inc. | Method for the treatment of skin tissues |
US11590248B2 (en) * | 2017-10-30 | 2023-02-28 | Hubbell Lighting, Inc. | Pulsing high intensity narrow spectrum light |
CA3092248A1 (en) | 2018-02-26 | 2019-08-29 | Mirko Mirkov | Q-switched cavity dumped sub-nanosecond laser |
USD854699S1 (en) | 2018-05-15 | 2019-07-23 | Carol Cole Company | Elongated skin toning device |
WO2021021066A1 (ru) * | 2019-07-30 | 2021-02-04 | Анатолий Анатольевич ТЕМИРОВ | Мобильное световое устройство для удаления запаха пота в области подмышек |
USD953553S1 (en) | 2020-02-19 | 2022-05-31 | Carol Cole Company | Skin toning device |
USD913508S1 (en) * | 2020-03-06 | 2021-03-16 | Cryoconcepts Lp | Device for dispensing carbon dioxide enhanced topical substances |
US11717698B1 (en) | 2020-04-23 | 2023-08-08 | Hugh McGrath, Jr. | Therapy, treatment, and process for photodynamic inactivation of COVID-19 |
US11602640B2 (en) * | 2020-05-16 | 2023-03-14 | Light Tree Ventures Holding B.V. | Irradiation device with adjustable beam angle |
US11247066B2 (en) * | 2020-06-15 | 2022-02-15 | Light Tree Ventures Holding B.V. | Irradiation device |
USD957664S1 (en) | 2020-07-29 | 2022-07-12 | Carol Cole Company | Skin toning device |
US11850319B2 (en) | 2020-09-29 | 2023-12-26 | Abl Ip Holding Llc | Techniques for directing ultraviolet energy towards a moving surface |
US20220096676A1 (en) | 2020-09-29 | 2022-03-31 | Abl Ip Holding Llc | Techniques for Directing Ultraviolet Energy Towards a Moving Surface |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4167669A (en) | 1971-09-09 | 1979-09-11 | Xenon Corporation | Apparatus for rapid curing of resinous materials and method |
EP0726083A2 (de) | 1995-02-07 | 1996-08-14 | ESC Medical Systems Ltd. | Verfahren und Vorrichtung zur Diagnose und Behandlung mit zusammengesetzter gepulster Erwärmung und photodynamischer Therapie |
EP0765674A2 (de) * | 1995-09-28 | 1997-04-02 | ESC Medical Systems Ltd. | Verfahren und Vorrichtung für die Psoriasisbehandlung mit pulsierter elektromagnetischer Strahlung |
WO1998023329A1 (en) * | 1996-11-25 | 1998-06-04 | Rachel Lubart | Device for light irradiation onto tissue |
US5798523A (en) * | 1996-07-19 | 1998-08-25 | Theratechnologies Inc. | Irradiating apparatus using a scanning light source for photodynamic treatment |
US5964749A (en) | 1995-09-15 | 1999-10-12 | Esc Medical Systems Ltd. | Method and apparatus for skin rejuvenation and wrinkle smoothing |
US5968034A (en) * | 1997-06-24 | 1999-10-19 | Laser Aesthetics, Inc. | Pulsed filament lamp for dermatological treatment |
WO2000002491A1 (en) | 1998-07-09 | 2000-01-20 | Curelight Ltd. | Apparatus and method for efficient high energy photodynamic therapy of acne vulgaris and seborrhea |
US6021344A (en) | 1996-12-04 | 2000-02-01 | Derma Technologies, Inc. | Fluorescence scope system for dermatologic diagnosis |
DE19838304A1 (de) * | 1998-08-24 | 2000-03-02 | Pierre Nicolas Foss | Externum oder Objektnah zu installierendes leuchtstoffhaltiges Mittel für phototherapeutische Zwecke |
WO2000028575A1 (de) | 1998-11-06 | 2000-05-18 | Spectrometrix Optoelectronic Systems Gmbh | Bestrahlungseinrichtung für therapeutische und kosmetische zwecke |
WO2000053114A1 (en) | 1999-03-05 | 2000-09-14 | Icn Photonics Limited | Skin wrinkle reduction using pulsed light |
EP0565331B1 (de) | 1992-04-09 | 2001-01-24 | ESC Medical Systems Ltd. | Gerät zur elektromagnetischen Therapie |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3521111A (en) | 1965-10-01 | 1970-07-21 | Mitsubishi Electric Corp | Discharge lamp having a fill including mercury and gallium iodide |
US3540789A (en) | 1968-04-08 | 1970-11-17 | Engelhard Hanovia Inc | Method of dosing vapor-discharge lamps with gallium |
DE2609273A1 (de) * | 1976-03-05 | 1977-09-08 | Mutzhas Maximilian F | Bestrahlungseinrichtung mit ultraviolett-strahlenquelle |
DE8232530U1 (de) * | 1982-11-20 | 1983-04-14 | Golf Gmbh & Co Kg, 4520 Melle | Bestrahlungsgeraet mit fahrbarem strahlungserzeuger ueber einer liege |
US5184044A (en) | 1990-08-13 | 1993-02-02 | Welch Allyn, Inc. | Dental curing lamp |
US5591219A (en) * | 1992-03-06 | 1997-01-07 | Dungan; Thomas E. | Frequency modulator |
DE4228311A1 (de) * | 1992-08-26 | 1994-03-03 | Brueck Gernot K | Phosphorfolien, insbesondere für die Anregung durch Hg-Lampen |
US5683380A (en) * | 1995-03-29 | 1997-11-04 | Esc Medical Systems Ltd. | Method and apparatus for depilation using pulsed electromagnetic radiation |
US6280438B1 (en) * | 1992-10-20 | 2001-08-28 | Esc Medical Systems Ltd. | Method and apparatus for electromagnetic treatment of the skin, including hair depilation |
DE4438294A1 (de) | 1994-10-26 | 1996-05-02 | Patent Treuhand Ges Fuer Elektrische Gluehlampen Mbh | Metallhalogenid-Entladungslampe für fotooptische Zwecke |
DE4440112A1 (de) * | 1994-11-11 | 1996-05-15 | Jan H Dr Wilkens | Bestrahlungsanordnung zur Behandlung von Hauterkrankungen |
DE29613075U1 (de) * | 1996-07-27 | 1997-11-27 | Shv Besonnungsanlagen Verwaltu | Besonnungsanlage |
US6214034B1 (en) * | 1996-09-04 | 2001-04-10 | Radiancy, Inc. | Method of selective photothermolysis |
US6162211A (en) * | 1996-12-05 | 2000-12-19 | Thermolase Corporation | Skin enhancement using laser light |
US6063108A (en) * | 1997-01-06 | 2000-05-16 | Salansky; Norman | Method and apparatus for localized low energy photon therapy (LEPT) |
JPH11238488A (ja) * | 1997-06-06 | 1999-08-31 | Toshiba Lighting & Technology Corp | メタルハライド放電ランプ、メタルハライド放電ランプ点灯装置および照明装置 |
US6016038A (en) * | 1997-08-26 | 2000-01-18 | Color Kinetics, Inc. | Multicolored LED lighting method and apparatus |
ATE328642T1 (de) * | 1997-10-08 | 2006-06-15 | Gen Hospital Corp | Phototherapeutische systeme |
US6223071B1 (en) * | 1998-05-01 | 2001-04-24 | Dusa Pharmaceuticals Inc. | Illuminator for photodynamic therapy and diagnosis which produces substantially uniform intensity visible light |
US6183496B1 (en) * | 1998-11-02 | 2001-02-06 | Datascope Investment Corp. | Collapsible hemostatic plug |
US6183500B1 (en) | 1998-12-03 | 2001-02-06 | Sli Lichtsysteme Gmbh | Process and apparatus for the cosmetic treatment of acne vulgaris |
US6514242B1 (en) * | 1998-12-03 | 2003-02-04 | David Vasily | Method and apparatus for laser removal of hair |
RU2181571C2 (ru) * | 1999-03-18 | 2002-04-27 | Закрытое акционерное общество "LC" | Устройство для терапевтической и косметологической фотообработки биотканей и способ его использования |
CA2369792A1 (en) | 1999-04-27 | 2000-11-02 | The General Hospital Corporation | Phototherapy method for treatment of acne |
US20030216795A1 (en) * | 1999-07-07 | 2003-11-20 | Yoram Harth | Apparatus and method for high energy photodynamic therapy of acne vulgaris, seborrhea and other skin disorders |
US20040122492A1 (en) * | 1999-07-07 | 2004-06-24 | Yoram Harth | Phototherapeutic treatment of skin conditions |
GB2368020A (en) * | 2000-10-18 | 2002-04-24 | Icn Photonics Ltd | Treatment of acne vulgaris skin condition by irradiation with light of specific wavelengths to target specific chromophores & stimulate collagen production |
US20030068297A1 (en) * | 2001-08-18 | 2003-04-10 | Deepak Jain | Composition and methods for skin rejuvenation and repair |
-
2001
- 2001-05-10 DE DE10123926A patent/DE10123926A1/de not_active Withdrawn
-
2002
- 2002-03-05 CA CA002435916A patent/CA2435916A1/en not_active Abandoned
- 2002-03-05 AT AT02726054T patent/ATE406192T1/de not_active IP Right Cessation
- 2002-03-05 EP EP02726054A patent/EP1365839B1/de not_active Expired - Lifetime
- 2002-03-05 DE DE10297083T patent/DE10297083D2/de not_active Expired - Lifetime
- 2002-03-05 JP JP2002571155A patent/JP4167901B2/ja not_active Expired - Fee Related
- 2002-03-05 EP EP10075516A patent/EP2258446A1/de not_active Withdrawn
- 2002-03-05 WO PCT/DE2002/000778 patent/WO2002072200A1/de active Application Filing
- 2002-03-05 DE DE50214709T patent/DE50214709D1/de not_active Expired - Lifetime
- 2002-03-05 DE DE10290911T patent/DE10290911D2/de not_active Expired - Fee Related
- 2002-03-05 AT AT02750510T patent/ATE484317T1/de active
- 2002-03-05 EP EP02750510A patent/EP1365840B1/de not_active Expired - Lifetime
- 2002-03-08 US US10/094,430 patent/US6902563B2/en not_active Expired - Fee Related
-
2004
- 2004-10-22 US US10/971,790 patent/US20050085878A1/en not_active Abandoned
-
2006
- 2006-11-30 US US11/606,702 patent/US20070073276A1/en not_active Abandoned
Patent Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4167669A (en) | 1971-09-09 | 1979-09-11 | Xenon Corporation | Apparatus for rapid curing of resinous materials and method |
EP0565331B1 (de) | 1992-04-09 | 2001-01-24 | ESC Medical Systems Ltd. | Gerät zur elektromagnetischen Therapie |
EP0726083A2 (de) | 1995-02-07 | 1996-08-14 | ESC Medical Systems Ltd. | Verfahren und Vorrichtung zur Diagnose und Behandlung mit zusammengesetzter gepulster Erwärmung und photodynamischer Therapie |
US5964749A (en) | 1995-09-15 | 1999-10-12 | Esc Medical Systems Ltd. | Method and apparatus for skin rejuvenation and wrinkle smoothing |
EP0765674A2 (de) * | 1995-09-28 | 1997-04-02 | ESC Medical Systems Ltd. | Verfahren und Vorrichtung für die Psoriasisbehandlung mit pulsierter elektromagnetischer Strahlung |
US5798523A (en) * | 1996-07-19 | 1998-08-25 | Theratechnologies Inc. | Irradiating apparatus using a scanning light source for photodynamic treatment |
WO1998023329A1 (en) * | 1996-11-25 | 1998-06-04 | Rachel Lubart | Device for light irradiation onto tissue |
US6021344A (en) | 1996-12-04 | 2000-02-01 | Derma Technologies, Inc. | Fluorescence scope system for dermatologic diagnosis |
US5968034A (en) * | 1997-06-24 | 1999-10-19 | Laser Aesthetics, Inc. | Pulsed filament lamp for dermatological treatment |
WO2000002491A1 (en) | 1998-07-09 | 2000-01-20 | Curelight Ltd. | Apparatus and method for efficient high energy photodynamic therapy of acne vulgaris and seborrhea |
DE19838304A1 (de) * | 1998-08-24 | 2000-03-02 | Pierre Nicolas Foss | Externum oder Objektnah zu installierendes leuchtstoffhaltiges Mittel für phototherapeutische Zwecke |
WO2000028575A1 (de) | 1998-11-06 | 2000-05-18 | Spectrometrix Optoelectronic Systems Gmbh | Bestrahlungseinrichtung für therapeutische und kosmetische zwecke |
DE19852524A1 (de) * | 1998-11-06 | 2000-05-18 | Spectrometrix Optoelectronic S | Bestrahlungseinrichtung für therapeutische und kosmetische Zwecke |
WO2000053114A1 (en) | 1999-03-05 | 2000-09-14 | Icn Photonics Limited | Skin wrinkle reduction using pulsed light |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005525193A (ja) * | 2002-05-15 | 2005-08-25 | ロエイ・メディカル・テクノロジーズ・リミテッド | 生体組織の正確な側部部分除去手術のための作業器具及びその使用法 |
WO2007029151A3 (en) * | 2005-09-06 | 2007-06-07 | Koninkl Philips Electronics Nv | Uv lamp for treatment of the skin |
EP2236150A4 (de) * | 2007-12-21 | 2012-02-29 | Asac Compania De Biotecnologia E Investigacion Sa | Verfahren zur erhöhung der therapeutischen wirksamkeit von curcuminoiden und analoga |
WO2017121656A1 (de) * | 2016-01-15 | 2017-07-20 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Flexible, umweltfreundliche lampenvorrichtung mit gasentladungslampe und verwendungen hiervon |
IT202100002870A1 (it) * | 2021-02-10 | 2022-08-10 | Giardinagroup S R L | Metodo e apparato per la reticolazione di una vernice |
Also Published As
Publication number | Publication date |
---|---|
JP4167901B2 (ja) | 2008-10-22 |
ATE406192T1 (de) | 2008-09-15 |
DE10290911D2 (de) | 2004-04-15 |
EP1365839A1 (de) | 2003-12-03 |
CA2435916A1 (en) | 2002-09-19 |
EP1365839B1 (de) | 2008-08-27 |
US20020161418A1 (en) | 2002-10-31 |
US6902563B2 (en) | 2005-06-07 |
US20070073276A1 (en) | 2007-03-29 |
DE10297083D2 (de) | 2004-07-01 |
EP2258446A1 (de) | 2010-12-08 |
ATE484317T1 (de) | 2010-10-15 |
US20050085878A1 (en) | 2005-04-21 |
DE50214709D1 (de) | 2010-11-25 |
EP1365840A1 (de) | 2003-12-03 |
EP1365840B1 (de) | 2010-10-13 |
JP2004532671A (ja) | 2004-10-28 |
DE10123926A1 (de) | 2002-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1365840B1 (de) | Bestrahlungsanordnung-für therapeutische zwecke | |
WO2002072199A1 (de) | Bestrahlungsanordnung und verfahren zur behandlung von akne und aknenarben | |
DE69333677T2 (de) | Eine therapeutische Behandlungsvorrichtung | |
EP0832668B1 (de) | Bestrahlungsvorrichtung, insbesondere zur kosmetischen, diagnostischen und therapeutischen Lichtanwendung | |
US6663658B1 (en) | Phototherapy method for treatment of acne | |
KR20070070156A (ko) | 여드름을 완화시키기 위해 광 및 유익제를 사용하는 피부치료법 | |
EP0790845A1 (de) | Behandlungsanordnung für lichttherapie und deren verwendung | |
DE10112289A1 (de) | Bestrahlungsanordnung und Verfahren zur Behandlung von Akne | |
WO2000028575A1 (de) | Bestrahlungseinrichtung für therapeutische und kosmetische zwecke | |
DE10128629A1 (de) | Hautpflaster, Licht bzw. Strahlung emittierende Vorrichtung hierfür, sowie Verfahren zur Anhebung des menschlichen Wohlbefindens | |
DE60126678T2 (de) | Therapeutische behandlungsvorrichtung | |
EP0023311B2 (de) | Medizinisches Bestrahlungsgerät | |
WO2011058048A1 (de) | Dermatologisches behandlungsgerät | |
DE102019006536B3 (de) | Vorrichtung und Verfahren zur Haut- und insbesondere Wundbehandlung unter Verwendung von Plasma | |
EP1226221B1 (de) | Leuchtstofffolie | |
DE10233839A1 (de) | UVA-Bestrahlungsanordnung | |
DE10240922A1 (de) | Bestrahlungsanordnung | |
DE10132823C2 (de) | Verwendung einer Lichtquelle zur Behandlung einer Hautkrankheit | |
WO2011038923A2 (de) | Verfahren zur medizinischen behandlung von patienten | |
Thiel | Low power laser therapy—an introduction and a review of some biological effects | |
EP1356848A1 (de) | Vorrichtung zur Behandlung der Haut mittels UV-Licht | |
CH477886A (de) | Vorrichtung zum Bestrahlen von lebendem Gewebe | |
DE10162147A1 (de) | UVB-Bestrahlungsanordnung | |
Schwarz et al. | Die Auswirkung der endoskopisch angewandten Hydrothermo-und Lasercoagulation auf die humane Magenwand in vivo | |
Schwarz et al. | Investigation of tissue lesion in endoscopic treatment of the human gastric wall with hydrothermosound and laser |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002750510 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2435916 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002571155 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002308355 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2002750510 Country of ref document: EP |
|
REF | Corresponds to |
Ref document number: 10290911 Country of ref document: DE Date of ref document: 20040415 Kind code of ref document: P |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10290911 Country of ref document: DE |